HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cosmetics ‘Are Not Risk-Free’; FDA Committed to Modernizing Regs – Commish Gottlieb

Executive Summary

FDA is committed to working with Congress to update cosmetics regulations and its related authorities, as “we have not been able to expand the scope of what we’re able to do commensurate with the expansion and the scope of this industry,” Commissioner Scott Gottlieb told House appropriators Feb. 26.

You may also be interested in...



Former US FDA Heads Urge Congress: Seize Opportunity For Cosmetic, Dietary Supplement Reform

Calling Congress’s failure to include cosmetic and dietary supplement riders in recent FDA user-fee reauthorization “a profound missed opportunity,” former FDA commissioners push for movement in the lame duck Congress in December.

Gottlieb Leaves FDA With Final Thought On What To Do About Cosmetics

Addressing for the last time the House Appropriations subcommittee with FDA oversight, Commissioner Scott Gottlieb shared his vision for sharpening cosmetics oversight in the absence of significant new resources.

PCPC: State Legislation, ‘Fake Science,' FDA’s Sunscreen Monograph Among Top 2019 Challenges

The Personal Care Products Council’s top execs identified key legislative, regulatory and public affairs challenges facing industry in 2019 during a Feb. 26 panel discussion at the group’s annual meeting in Palm Beach, Fla.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148591

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel